BioRestorative Therapies (BRTX) EBIT (2010 - 2025)

BioRestorative Therapies (BRTX) has reported EBIT for 16 consecutive years, with -$3.8 million the latest figure, recorded in Q4 2025.

• For the quarter ending Q4 2025, EBIT fell 42.2% year-over-year to -$3.8 million; the trailing twelve-month figure through Dec 2025 stood at -$15.6 million (down 35.41% YoY), and the FY2025 full-year result was -$15.6 million, down 35.41% from the prior year.
• EBIT fell to -$3.8 million in Q4 2025 per BRTX's latest filing, from -$3.7 million in the prior quarter.
• Across five years, EBIT topped out at -$2.3 million in Q3 2024 and bottomed at -$15.1 million in Q1 2021.
• Historically, EBIT has averaged -$4.4 million across 5 years, with a median of -$3.8 million in 2025.
• The sharpest annual moves came in 2021 and 2022: EBIT slumped 1738.2% in 2021, then soared 66.43% in 2022.
• Over 5 years, EBIT stood at -$4.0 million in 2021, then declined by 16.78% to -$4.7 million in 2022, then jumped by 31.21% to -$3.2 million in 2023, then increased by 16.47% to -$2.7 million in 2024, then sank by 42.2% to -$3.8 million in 2025.
• According to Business Quant data, EBIT over the past three periods registered -$3.8 million, -$3.7 million, and -$3.3 million for Q4 2025, Q3 2025, and Q2 2025 respectively.